| Events Column |
|
|
| 3/20 5:00 pm - 7:30 pm. Opening Reception. UConn Medical Illustration
Exhibition. Runs March 17 - May 10. Benton Museum, Storrs. more |
|
|
| 3/23 11:00 am - 7:00 pm. StemCONN
09 International Stem Cell Symposium. Omni New Haven Hotel at Yale, 155
Temple Street, New Haven. more |
|
|
| 3/24 8:30 am - 5:30 pm. StemCONN
09 International Stem Cell Symposium. Omni New Haven Hotel at Yale, 155
Temple Street, New Haven. more |
|
|
| 3/25 3:30 pm - 6:30 pm. CURE/Yale
BioHaven: CellDesign. Anlyan Center, 300 Cedar Street, New Haven. more |
|
|
| 3/30 - 4/3 6:00 pm - 8:30 pm. YBPS Presents "The Business of Biotechnology
2009" with Constance McKee. Week-long seminar. Yale School of
Management, 135 Prospect Street, New Haven. more |
|
|
| 4/23 3:30 pm - 6:30 pm. CURE/Yale
BioHaven: Cara Therapeutics. Anlyan Center, 300 Cedar Street, New
Haven. more |
|
|
| 5/1 9:00
am - 8:30 pm. Pitch presentations begin at Yale Entrepreneurial Society
Y50K Competition. more |
|
|
| 5/6 3:30 pm - 6:30 pm. CURE/Yale
BioHaven: Affomix. Anlyan Center, 300 Cedar Street, New Haven. more |
|
|
|
|
A Cure for What Ails Us
From the desk of Paul
Pescatello, President and CEO of CURE
 What’s
roiling our economy is the growing fear that the experts don’t have a
clear sense of what ails us, much less what to do about it. But as to
science policy itself, the Obama administration is clear,
decisive and effective. In lifting the Bush era restrictions on
embryonic stem cell research, President Obama reinforces our strengths
– basic and translational research – and builds a solid foundation for
a new wave of American scientific innovation. Where does this leave
Connecticut? Well positioned.
For the full story |
|
New Study Underscores
Biopharma Contribution
An economic study issued March 5
underscores the contribution to Connecticut’s economy of its
pharmaceutical research and biotechnology companies. "Biotech, medical
devices, and pharma
are the engines driving the
knowledge-based 21st-century Connecticut economy," said Paul
Pescatello, president and CEO of CURE.
Separately, Pescatello testified March 9 in Hartford against
several bills that would complicate physicians' practice of medicine
and add regulation to the interactions between doctors and
biopharmaceutical
companies.
For
the
full story |
|
|
Shelton’s Cara Therapeutics
Holds Open House
 Cara Therapeutics opened its doors
to neighbors February 26 with a presentation and wine & cheese
reception at the company’s state-of-the-art headquarters and research
facility at One Parrott Drive in Shelton.
For the
full story |
|
|
Life Sciences Drew Two Thirds of CT VC in
2006-08
Almost two thirds of the venture capital investment in Connecticut the
past three years has been in the Life Sciences area, according to a
CURE analysis of figures in the MoneyTree™ report, supplied by
PricewaterhouseCoopers and the National Venture Capital Association,
based on data provided by Thomson Reuters.
For the
full story |
|
|
Nominations Due for 2009 Medal
of Science
The State of Connecticut is calling for
nominations for the 2009 Medal of Science. A nomination form may be
downloaded here.
Nominations are due April 3. The Medal of Science is Connecticut’s
highest honor for scientists and engineers. It is designed to recognize
extraordinary achievements in scientific fields crucial to
Connecticut’s economic competitiveness and social well-being.
For the
full story |
|
|
CURE Member News Digest
 454
Life Sciences reports sequencing of coral samples
Achillion names Joseph
Truitt Vice President
Alexion tells of Canadian
approval
Bristol-Myers Squibb
pleased with 4Q results
Cara Therapeutics
initiates Phase 2 trial
CellDesign unveils new
website
Connecticut Innovations
invests more in FMP
CuraGen encouraged by
recent data
Danbury Hospital garners
HealthGrades award
GlaxoSmithKline in license
pact for HIV/AIDS drug
Hartford Hospital has new
heart attack procedure
HistoRx names Kathleen
Adams Vice President
Ipsogen appoints new
chief medical officer
Johnson
& Johnson reports catheter approval
Neurogen
to sell patent estate
Pfizer and
Wyeth to merge
PhRMA
supports comparative clinical
effectiveness research
Protein
Sciences not to be acquired by Emergent BioSolutions
Rib-X
closes on $25 million financing
Winstanley
Enterprises purchases U.S. Repeating Arms site
UConn researchers create
two new human stem cell lines
Yale identifies cytokine
with bowel disease role
For
the full story |
|
